DoubleLine ETF Adviser’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
DoubleLine ETF Adviser's REGN Position: Q2 2026 in Review
DoubleLine ETF Adviser reduced its Regeneron Pharmaceuticals (REGN) stake by 8.1% in Q2 2026, selling an estimated $72.8K and leaving 1,209 shares worth $754K. The position accounts for 0.31% of the portfolio, ranked #87.
DoubleLine ETF Adviser first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.02M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- DoubleLine ETF Adviser held 1,209 shares of Regeneron Pharmaceuticals worth $754K as of Q2 2026.
- DoubleLine ETF Adviser sold 107 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $72.8K.
- Regeneron Pharmaceuticals made up 0.31% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #87 holding.
- DoubleLine ETF Adviser first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
- DoubleLine ETF Adviser's Regeneron Pharmaceuticals position peaked at $1.02M in Q1 2026.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.